Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 630 across all filing types
Latest filing 2026-05-22 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 98% confidence The document is an official announcement by 江苏浩欧博生物医药股份有限公司 detailing the 2025年度权益分派 (equity distribution) scheme, including cash dividend per share, record date, ex-dividend date, payment date, tax handling, and shareholder eligibility. It specifically sets out the dividend amount (0.20元 per share), related dates and procedures. This matches the definition of a Notice of Dividend Amount.
2026-05-22 Chinese
江苏浩欧博生物医药股份有限公司2026年第一次临时股东会会议资料
AGM Information Classification · 95% confidence The document is titled as "2026年第一次临时股东会会议资料" which translates to "2026 First Extraordinary General Meeting (EGM) Meeting Materials". It contains detailed information about the meeting agenda, voting procedures, meeting rules, and a specific proposal regarding the revision of the remuneration management system for directors and senior management. The document is clearly a set of materials prepared for a shareholders' meeting, including instructions, agenda, and proposals to be voted on. It is not a report of voting results, nor is it a proxy solicitation or a report publication announcement. It is not an annual or interim report, nor an earnings release or audit report. The content fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or Extraordinary General Meeting. Although the meeting is an extraordinary shareholders meeting, the category AGM-R is the closest and most appropriate classification for meeting materials. The document length is 3153 characters, which is consistent with meeting materials rather than a full report. Therefore, the classification is AGM-R with high confidence.
2026-04-30 Chinese
江苏浩欧博生物医药股份有限公司关于召开2026年第一次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2026 first extraordinary general meeting of shareholders (临时股东会) for Jiangsu Haobo Biopharmaceutical Co., Ltd. It details the meeting date, voting methods, agenda items, and procedural instructions for shareholders. It does not contain financial statements or results, nor is it a transcript or presentation. It is an announcement of a shareholders meeting, specifically a notice to shareholders about the meeting and voting procedures. This fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document length is under 5,000 characters and it is not a report publication announcement or regulatory filing. Therefore, the best classification is PSI with high confidence.
2026-04-27 Chinese
江苏浩欧博生物医药股份有限公司董事、高级管理人员薪酬管理制度
Remuneration Information Classification · 95% confidence The document is titled '董事、高级管理人员薪酬管理制度' which translates to 'Remuneration Management System for Directors and Senior Management'. It details the principles, structure, management, and adjustment of remuneration for directors and senior management of the company. It references relevant laws and governance codes, and outlines the remuneration policy and procedures. There is no financial data, earnings, or report publication mentioned. The content is focused on compensation policies and governance related to remuneration. Therefore, this document fits the category of Remuneration Information (DEF 14A). The document length is 2495 characters, which is consistent with a detailed policy document rather than a brief announcement or report publication.
2026-04-27 Chinese
江苏浩欧博生物医药股份有限公司关于召开2025年年度暨2026年第一季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of an investor performance briefing meeting (业绩说明会) for the 2025 annual and 2026 first quarter results. It provides details on the meeting time, location, participation method, and contact information. It references that the 2025 annual report and 2026 first quarter report have already been published on March 18 and April 28, respectively, but this document itself is not the report or the transcript of the meeting. The document is short (1442 characters) and serves as a notice for an upcoming investor presentation event rather than containing financial data or detailed analysis. Therefore, it fits best as an Investor Presentation (IP) announcement or notice. Given the detailed meeting information and focus on investor communication, the classification is Investor Presentation (IP).
2026-04-27 Chinese
江苏浩欧博生物医药股份有限公司2026年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2026年第一季度报告" which translates to "2026 First Quarter Report". It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management assurances about the accuracy of the quarterly report. The report is unaudited as indicated. The content is comprehensive and covers a period shorter than a full fiscal year (the first quarter of 2026). This matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (over 14,000 characters) and contains actual financial statements and analysis, not just an announcement or certification. Therefore, the correct classification is IR with high confidence.
2026-04-27 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.